Dr. Heather Sandison, a leading expert in Alzheimer’s Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer’s Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline.
Novartis’ urticaria drug meets all endpoints in Phase III trials – Pharmaceutical Technology
Remibrutinib is forecasted to generate $237m in 2034 in US sales, as per GlobalData’s Expiry model. Image Credit: Michael Derrer Fuchs / Shutterstock. Novartis’ remibrutinib